| DIRECT COMPETITOR COMPARISON | |
| ACUR | ELI | ENDP | PTIE | Industry | | Market Cap: | 239.76M | N/A | 2.29B | 216.00M | 72.10M | | Employees: | 15 | N/A | 1,216 | 48 | 38 | | Qtrly Rev Growth (yoy): | -79.20% | N/A | 14.00% | -87.60% | 3.00% | | Revenue (ttm): | 10.87M | N/A | 1.42B | 25.08M | 17.49M | | Gross Margin (ttm): | 32.94% | N/A | 75.15% | -5.42% | 63.53% | | EBITDA (ttm): | -8.48M | N/A | 461.38M | -7.66M | -6.12M | | Oper Margins (ttm): | -79.22% | N/A | 27.58% | -31.75% | -3.79% | | Net Income (ttm): | -14.74M | N/A | 197.58M | -4.56M | N/A | | EPS (ttm): | -0.322 | N/A | 1.685 | -0.108 | -0.19 | | P/E (ttm): | N/A | N/A | 11.61 | N/A | 16.32 | | PEG (5 yr expected): | N/A | N/A | 0.78 | N/A | 1.30 | | P/S (ttm): | 21.10 | N/A | 1.63 | 8.67 | 3.29 |
|
| ELI = Elite Pharmaceuticals Inc. | | ENDP = Endo Pharmaceuticals Holdings Inc. | | PTIE = Pain Therapeutics Inc. | | Industry = Drug Delivery | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 55.77 | -0.29% | 56.45B | 12.16 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.89 | -0.35% | 13.85B | 16.03 | | Genzyme Corp. | GENZ | 49.08 | -0.69% | 13.02B | 27.98 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 45.92 | -0.43% | 41.32B | 17.76 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.89 | 0.04% | 8.90B | 1018.16 | | Teva Pharmaceutical Industries Limited | TEVA | 52.17 | -0.51% | 45.96B | 47.73 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.60 | -0.45% | 3.99B | 19.38 | | King Pharmaceuticals Inc. | KG | 11.44 | 1.24% | 2.84B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.08 | -0.33% | 5.52B | 110.92 | | Pfizer Inc. | PFE | 18.13 | 2.08% | 146.30B | 15.06 | | Johnson & Johnson | JNJ | 64.23 | -0.03% | 177.22B | 14.03 | | GlaxoSmithKline plc | GSK | 41.58 | -1.12% | 105.41B | 13.24 | | Sanofi-Aventis | SNY | 38.7681 | 0.10% | 101.23B | N/A | | Novartis AG | NVS | 54.60 | -1.32% | 124.01B | 16.35 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 40.89 | 0.22% | N/A | N/A | | AstraZeneca plc | AZN | 45.40 | -0.66% | 65.83B | 9.12 | | Abbott Laboratories | ABT | 53.425 | 0.35% | 82.63B | 14.47 | | Bristol-Myers Squibb Co. | BMY | 24.94 | 0.16% | 49.41B | 12.90 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | ENDP | | Biotech Stocks: Endo, Celgene lead drug stocks lower
Tue 3:53pm -
at MarketWatch | | • | ENDP | | Corrections: Tuesday's biggest gaining and declining stocks
Tue 11:31am -
at MarketWatch | | • | ENDP | | Endo Pharm downgraded by Barclays Capital
Tue 6:29am -
Briefing.com | | • | PTIE | | Today's 5-Star Movers
Fri, Dec 4 -
at Motley Fool | | • | ENDP | | [$$] Macy's, Costco Fall; Comcast Climbs 6.5%
Thu, Dec 3 -
at The Wall Street Journal Online | | • | ENDP | | FDA wants information on ârare but serious eventsâ linked to Endoâs Aveed
Thu, Dec 3 -
at bizjournals.com | | • | PTIE | | King Beats, but Earnings Down
Thu, Nov 5 -
Zacks.com | | • | PTIE | | PAIN THERAPEUTICS INC Financials
Wed, Nov 4 -
EDGAR Online Financials | | • | PTIE | | Pain Therapeutics to Present at the Credit Suisse Healthcare Conference
Wed, Nov 4 -
GlobeNewswire | | • | PTIE | | PAIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
Fri, Oct 30 -
EDGAR Online | | • | PTIE | | PAIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition
Thu, Oct 29 -
EDGAR Online | | • | ELI | | Elite Commences Quotation On OTC Bulletin Board Under Ticker Symbol ELTP
Thu, May 21 -
GlobeNewswire | | • | ELI | | ELITE PHARMACEUTICALS INC /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Notice of Delisting or
Wed, May 6 -
EDGAR Online | | • | ELI | | Elite Initiates Process to Delist Its Common Stock From NYSE Amex and Commence Quotation On OTC Bulletin Board
Thu, Apr 30 -
GlobeNewswire | | • | ELI | | Elite Initiates Process to Delist Its Common Stock From NYSE Amex and Commence Quotation On OTC Bulletin Board
Thu, Apr 30 -
GlobeNewswire | | • | ELI | | ELITE PHARMACEUTICALS INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an
Wed, Apr 29 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
0.11% Nasdaq 
0.14%
Competitors
